Genetics and biomarker in bladder cancer for optimized clinical decision-making and improved outcomes

Urothelial carcinoma is the second most common urological malignancy after prostate cancer and with approximately estimated 79,000 newly diagnosed cases and 16,800 deaths in the United states in 2017 a significant burden of morbidity and mortality (1).